Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KT-301
- Development stage
- Phase 3
- Lead developer
- Kibow Therapeutics
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
KT-301 is an encapsulated consortium of proprietary strains of commensal bacteria, formulated as a live biotherapeutic product. It is designed to metabolize uremic toxins and improve gut microbiome health in patients with chronic kidney disease (CKD). The formulation includes specific strains such as *S. thermophilus KB19*, *L. acidophilus KB27*, *B. longum KB31*, and *B. longum XX00*, along with complementary soluble fibers. The drug aims to restore the gut microbiome and enhance the removal of uremic toxins associated with CKD progression[1][2]. KT-301 is administered orally in capsule form and is currently being investigated for its safety and efficacy in halting or slowing kidney disease progression[1][2].
- Other names
- KT-301 US-APR2020KT301 US-APR2020KT 301 US-APR2020
02
Targets
UTs (Uremic toxins in the gut lumen)
Beyond the preview
Go deeper on KT-301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KT-301.